Documents reviewed by the Wall Street Journal confirm AIDS advocates’ suspicions that Abbott Laboratories hiked the price of Norvir by 400% in December 2003 in order to improve sales of Kaletra, according to a story in today’s paper. Norvir is generally prescribed to boost the effectiveness of Kaletra’s competitors.